In conclusion, this study suggested that the expressions of S100A6, S100A10, S100A16, and SDC1 were upregulated in PAAD, which might be crucial biomarkers in the progression of PAAD. This evidence concerns the gene S100A6 and pancreatic adenocarcinoma.